Forest Laboratories Inc (FRX.N)
44.84USD
11:36am EDT
$0.18 (+0.40%)
$44.66
$44.60
$44.91
$44.53
57,606
411,948
$44.91
$31.72
About
Overall
| Beta: | 0.77 |
| Market Cap (Mil.): | $11,968.12 |
| Shares Outstanding (Mil.): | 267.98 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| FRX.N | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 38.06 | 37.87 |
| EPS (TTM): | -0.24 | -- | -- |
| ROI: | -- | 19.42 | 18.70 |
| ROE: | -- | 20.10 | 19.53 |
UPDATE 4-U.S. drugmaker Perrigo to buy Ireland's Elan for $8.6 bln
DUBLIN, July 29 - U.S. drugmaker Perrigo agreed to buy Elan for $8.6 billion in a deal that will hand it tax savings from being domiciled in Ireland and royalties from a blockbuster multiple sclerosis treatment.
REFILE-Deals of the day -- mergers and acquisitions
July 25 - The following bids, mergers, acquisitions and disposals were reported by 1330 GMT on Thursday:
UPDATE 1-Market Chatter-Corporate finance press digest
July 25 - The following corporate finance-related stories were reported by media on Thursday:
Market Chatter-Corporate finance press digest
July 25 - The following corporate finance-related stories were reported by media on Thursday:
Elan seeks bids from Allergan, Forest: sources
NEW YORK - Irish drugmaker Elan Corp is seeking first-round bids next week after drawing interest from a few drugmakers including Allergan Inc and Forest Laboratories Inc , several people familiar with the matter said on Friday.
UPDATE 1-Elan seeks bids from Allergan, Forest -sources
NEW YORK, July 12 - Irish drugmaker Elan Corp is seeking first-round bids next week after drawing interest from a few drugmakers including Allergan Inc and Forest Laboratories Inc, several people familiar with the matter said on Friday.
First-round bids for Elan due next week -sources
NEW YORK, July 12 - Elan Corp is seeking first-round bids next week after drawing interest from a few drugmakers including Allergan Inc and Forest Laboratories Inc, several people familiar with the matter said on Friday.
Forest Labs says trial results positive for hypertension drug
June 27 - Forest Laboratories Inc said on Thursday that combining Bystolic, the brand name for nebivolol, and valsartan to treat hypertension in a clinical trial was more effective at lowering blood pressure than either nebivolol or valsartan alone at eight weeks.
Wall St. plunges, S&P posts biggest drop since Nov 2011
NEW YORK - Stocks fell more than 2 percent on Thursday, extending the previous day's sharp decline as investors fretted over the Federal Reserve's plan to begin reducing its stimulus later this year if the economy strengthens. | Video
US STOCKS-Wall Street drops in wake of Fed stimulus wind-down plan
NEW YORK, June 20 - The Federal Reserve's plans to begin winding down its massive monetary stimulus later this year hurt shares on Wall Street for a second day Thursday, putting the S&P on track for its worst two-day run in seven months.
Competitors
| Price | Change | |
|---|---|---|
| Pfizer Inc. (PFE.N) | $29.27 | +0.16 |
| Johnson & Johnson (JNJ.N) | $94.02 | +0.25 |
| Novartis AG (NOVN.VX) | CHF67.55 | +0.95 |
| Roche Holding Ltd. (ROG.VX) | CHF228.70 | +0.70 |
| Abbott Laboratories (ABT.N) | $36.85 | +0.01 |
| AstraZeneca plc (AZN.L) | 3,332.50p | -1.50 |
| GlaxoSmithKline plc (GSK.L) | 1,712.50p | 0.00 |
| Eli Lilly & Co. (LLY.N) | $53.65 | +0.15 |
| Teva Pharmaceutical Industries Limited (TEVA.TA) | 13,920.00₪ | -200.00 |
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Trading Report for (FRX). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: ValuEngine, Inc.
|
$25.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
|
Provider: MacroRisk Analytics/EconomicInvestor
|
$15.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

